Abiraterone Acetate Withdrawal Syndrome: Does It Exist
oleh: Hélène Gauthier, Guilhem Bousquet, Damien Pouessel, Stéphane Culine
| Format: | Article |
|---|---|
| Diterbitkan: | Karger Publishers 2012-07-01 |
Deskripsi
In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy. We report the case of a patient who experienced a confirmed PSA decrease of ≥50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.